Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01999673 · ClinicalTrials.gov registry record · Phase 3
Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer
A Phase 3 study, sponsored by Peregrine Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 582
- Enrollment target
NCT01999673 is a Phase 3 study that has completed, run by Peregrine Pharmaceuticals. The registered enrollment target is 582 participants.
The verdict
NCT01999673, a Phase 3 study, has completed, sponsored by Peregrine Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 582 participants
- Enrollment target
Study Summary
The primary purpose of this research study is to see whether adding bavituximab (an investigational drug) to the standard chemotherapy drug docetaxel, will improve the results of the treatment for non-small-cell lung cancer.
Interventions
- DRUG Docetaxel
- BIOLOGICAL bavituximab
- OTHER Placebo (for bavituximab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 582 participants |
| Start Date | 2013-12 |
| Est. Completion | 2017-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01999673
The ClinicalTrials.gov registry entry for NCT01999673 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 582 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Peregrine Pharmaceuticals, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Docetaxel is the first listed.
NCT01999673 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01999673 about?
NCT01999673 is a clinical study titled "Phase 3 Study of Bavituximab Plus Docetaxel Versus Docetaxel Alone in Patients With Late-stage Non-squamous Non-small-cell Lung Cancer". The primary purpose of this research study is to see whether adding bavituximab (an investigational drug) to the standard chemotherapy drug docetaxel, will improve the results of the treatment for non-small-cell lung cancer.
What is the current status of trial NCT01999673?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 582 participants. The study started on 2013-12. Estimated completion is 2017-03.
What interventions are being tested in trial NCT01999673?
The interventions under investigation include: Docetaxel (DRUG), bavituximab (BIOLOGICAL), Placebo (for bavituximab) (OTHER).
Who is sponsoring clinical trial NCT01999673?
This trial is sponsored by Peregrine Pharmaceuticals, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.